1986年以来,三苯氧胺已经成为早期乳腺癌患者辅助内分泌治疗的首选。有资料显示[1],三苯氧胺辅助治疗绝经后乳腺癌患者连续5年,肿瘤复发率和患者死亡率都明显减少,在50~59岁、60~69岁和70岁以上3个年龄组,其相对应的复发风险率分别减少34%、44%和51%,相对应的死亡风险率分别减 Since 1986, tamoxifen has become the preferred adjuvant endocrine therapy for patients with early-stage breast cancer. There are data [1], tamoxifen adjuvant treatment of postmenopausal breast cancer patients for 5 consecutive years, the tumor recurrence rate and patient mortality were significantly reduced in 50 to 59 years old, 60 to 69 years old and over the age of 70 three age groups The corresponding risk of recurrence decreased by 34%, 44% and 51% respectively, while the corresponding risk of death was reduced by